Compare KMT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | NVCR |
|---|---|---|
| Founded | 1938 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | KMT | NVCR |
|---|---|---|
| Price | $28.55 | $12.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $24.60 | ★ $28.42 |
| AVG Volume (30 Days) | 804.7K | ★ 1.8M |
| Earning Date | 02-04-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,982,871,000.00 | $642,269,000.00 |
| Revenue This Year | $7.69 | $9.75 |
| Revenue Next Year | $3.82 | $5.62 |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $17.30 | $10.70 |
| 52 Week High | $29.89 | $34.13 |
| Indicator | KMT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.52 | 51.80 |
| Support Level | $28.39 | $12.30 |
| Resistance Level | $29.89 | $13.94 |
| Average True Range (ATR) | 0.57 | 0.66 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 48.70 | 58.41 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.